Collectively, these results demonstrate that a sequential TLR agonist activation strategy, which accommodates the temporal dynamics of TLR3 upregulation, significantly enhances the antitumor efficacy of DC vaccines, leading to superior tumor control and improved survival outcomes in murine glioma models. Here, TLR3 is linked to central nervous system cancer.